Conference Description

January 13, 2007
The Westin Fort Lauderdale
400 Corporate Drive
Fort Lauderdale, FL
(954) 772-1331

Tell a friend about this conference
Download the brochure for this conference

See how attendees evaluated this conference

CME Credits 4.7 AMA PRA Category I Credits*

Nonrefundable registration fee: $0.

Target Audience: Endocrinologists and Health Care Professionals Treating Endocrine Disorders

Learning Objectives:
The intimate setting of the conference will maximize learning and discussion and will enable endocrinologists to learn first hand from thought leaders in their field. Among the proposed objectives will be:

1. review the rapidly emerging role of incretin based therapy for diabetes based on incretin mimetics and DPP4 inhibitors
2. discuss the use of pramlintide in Type 1 and Type 2 diabetes
3. explain and update the role of PPAR’s in cardiovascular disease
4. explain inhaled insulin as a novel method of insulin administration
5. discuss controversies and approaches in the management of thyroid nodules
6. discuss new modalities,including vit D analogues,for treating 2°hyperparathyroidism in patients with diabetes and renal insufficiency

Agenda:

7:15–7:50 am		Continental Breakfast and Registration
7:50–8:00 am		Welcome and Introduction Paul Jellinger, MD
8:00–8:50 am		The Expanding Role of Incretin Based Therapy: GLP-1 Agonists, DPP4 Inhibitors Daniel Drucker, MD
8:50–9:40 am		Pramlintide: Scientific Overview David Kendall, MD
9:40–10:30 am		PPARs in Cardiovascular Disease Jorge Plutzky, MD
10:30–11:00 am		Exhibits and Break
11:00-11:40		Advances in Insulin Administration: The Role of Inhaled Insulin Bernard Zinman, MD
11:40 am–12:20 pm		Controversies in the Management of Thyroid Nodules Susan Mandell., MD
12:20–1:15 pm		2° Hyperparathyroidism: Treating Patients with Diabetes and Renal Insufficiency Larry Blonde, MD

Faculty:
Daniel Drucker, MD, FRCPC
Professor of Medicine, Endocrinology
Division at the University of Toronto
Director of the Banting and
Best Diabetes Centre at the University of Toronto
Toronto, Canada

David M. Kendall, MD
Endocrinology
Executive Director, Medical Affairs
Amylin Pharmaceuticals
San Diego, CA

Jorge Plutzky, MD
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Larry Blonde, MD
Chief of Endocrinology and Metabolic
Diseases and Vice Chairman of Medicine
Ochsner Clinic
New Orleans, LA

Susan Mandel, MD
Associate Professor of Medicine
and Radiology, University of
Pennsylvania School of Medicine
Program Director, Fellowship Training Program in Endocrinology, Diabetes and Metabolism
University of Pennsylvania School of Medicine
Philadelphia, PA

Bernard Zinman, MD
Director of the Leadership Sinai Centre for Diabetes
Senior Scientist at the Samuel Lunenfeld Research Institute
Professor of Medicine at the University of Toronto
Toronto, Canada

Program Planning Committee:
Chairman
Paul S. Jellinger, MD, FACE
Past President, American College of Endocrinology
The Center for Diabetes and Endocrine Care
Profesor of Medicine, Voluntary Faculty
University of Miami School of Medicine

Co-chairmen
Sam Lerman, MD, FACE
The Center for Diabetes and Endocrine Care
Associate Professor of Medicine, Voluntary Faculty
University of Miami School of Medicine

Louis Chaykin, MD
Aventura Hospital and Medical Center
Clinical Associate Professor of Medicine at Nova Southeastern University of
Medical Sciences

Activity Director: Alan Goodstat, LCSW

*Continuing Education Information
The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 4.7 AMA PRA Category I Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 5.7 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity. In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented. Such disclosure will be made available on the day of the program.

Funding
This activity was supported through educational grants from the following companies: Abbott Laboratories, Amylin, Novo Nordisk, Solvay, Takeda